<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00105313</url>
  </required_header>
  <id_info>
    <org_study_id>MI-CP107</org_study_id>
    <nct_id>NCT00105313</nct_id>
  </id_info>
  <brief_title>Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia</brief_title>
  <official_title>A Phase I Open-Label Dose Escalation Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <brief_summary>
    <textblock>
      For primary objectives, we will determine the MTD and examine clinical responses and immune&#xD;
      cell populations to determine an OBD, and describe the safety and tolerability of MEDI-507.&#xD;
&#xD;
      For the secondary objectives we will look at the antitumor activity of MEDI 507, PK, serum&#xD;
      concentrations, and immunogenicity of MEDI-507, as well as time courses of depletion and&#xD;
      recovery of CD2 positive and total T-Cell populations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    After review of safety events and have decided that further dose escalation of MEDI-507 as a&#xD;
    single agent is not feasible.&#xD;
  </why_stopped>
  <start_date>February 2005</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the maximum tolerated dose (MTD) or the optimal biological dose</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>(OBD) of MEDI-507 based on safety and tolerability of MEDI-507 in patients with</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>CD-2 positive lymphoproliferative disorders.</measure>
  </primary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Lymphoma</condition>
  <condition>Leukemia</condition>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-507</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Individuals may be eligible for this study if they are 18 years of age or older and:&#xD;
&#xD;
          -  Have one of the following types of T-Cell Lymphoproliferative disorders such as&#xD;
             Cutaneous T-cell Lymphoma (CTCL), Peripheral T-cell Lymphoma (PCTL), Large Cell&#xD;
             Lymphoma (LGL), or Adult T-cell Lymphoma (ATL). Patients should have disease that is&#xD;
             resistant or refractory to the front-line therapy, except ATL patients for whom there&#xD;
             is no standard therapy.&#xD;
&#xD;
          -  At least 30% of tumor cells must be CD2 positive.&#xD;
&#xD;
          -  Karnofsky Performance status of greater than or equal to 70% (able to care for&#xD;
             themselves; but unable to carry on normal activity or to do active work).&#xD;
&#xD;
          -  At least 3 weeks must have passed since prior systemic cytotoxic chemotherapy,&#xD;
             prolonged or cytolytic steroid therapy or major surgery, and all treatment-related&#xD;
             toxicities must have resolved prior to the first MEDI-507 administration (except&#xD;
             thrombocytopenia).&#xD;
&#xD;
          -  Have no prior treatment with MEDI-507.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luz Hammershaimb, MD</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USC/Norris Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center, Lombardi Comprehensive Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Ctr &amp; Research Institute Div of Hem/Onc</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland School of Medicine, Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts New England Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nevada Cancer Institute</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kimmel Cancer Center, Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <study_first_submitted>March 11, 2005</study_first_submitted>
  <study_first_submitted_qc>March 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2005</study_first_posted>
  <last_update_submitted>June 12, 2007</last_update_submitted>
  <last_update_submitted_qc>June 12, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

